Kerrisdale Capital Management, known for its activist short positions, has given Prothena the unwanted title of the “next big biotech blowup.”

An Amgen-backed $25 million series B sets startup Fortuna to move candidates against Parkinson’s disease and spinal cord injury into the clinic.

We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.

New startup biotech Oyster Point Pharmaceuticals came out of stealth today with $22 million led by venture capital firms New Enterprise Associates (NEA) and…

The round equips a team last seen leading Okairos to a €250 million buyout by GSK to take off-the-shelf neoantigen cancer vaccine into the clinic.

New York venture firm Aisling Capital has raised a solid chunk of cash for clinical-stage biotechs as it looks to build on some of its recent successes.

Bay area biotech AvidBiotics has decided that its two development programs would do better as separate companies.

California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science…

Venture Capital